India Patent Office Weighs Natco CL Suit For Generic Of Bayer’s Nexavar
This article was originally published in PharmAsia News
Executive Summary
India’s patent office is expected to rule soon in a case that has India’s Natco seeking a compulsory license to market a generic version of Bayer’s Nexavar for treating kidney cancer.